person · Reporting owner

SAUNDERS BRENT L

Disclosed activity across 7 companies

Tapewire entity: 11572
SEC CIK: 0001268854

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARS Pharmaceuticals, Inc.SPRY · Entity 883	Director	June 24, 2026	June 26, 2026
Bausch & Lomb CorpBLCO · Entity 3756	Director · Chairman of the Board and CEO	August 05, 2026	August 07, 2026
BridgeBio Pharma, Inc.BBIO · Entity 3360	Director	June 22, 2022	June 24, 2022
CISCO SYSTEMS, INC.CSCO · Entity 2802	Director	December 08, 2022	December 12, 2022
SkinHealth Systems Inc.SKIN · Entity 6863	Director · Chairman	June 16, 2025	June 18, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARS Pharmaceuticals, Inc.

Report date June 24, 2026 · Filed June 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.54 · Expires 2036-06-23	Direct	30,000	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Bausch & Lomb Corp

Report date August 05, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, No Par ValueSEC Table I · non-derivative	Direct	1,256,037	Ending reported balance After 2026-08-05 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-05 · Tax withholding · Disposed 4,231 · Balance 974,158 F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Row 2 · 2026-08-05 · Grant · Acquired 281,879 · Balance 1,256,037 F2: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date.

Filing footnotes · ownership attribution and instrument terms

F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units.

F2: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date.

BridgeBio Pharma, Inc.

Report date June 22, 2022 · Filed June 24, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2032-06-22	Direct	104,921	Reported balance After 2022-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-22 · Grant · Acquired 104,921 · Balance 104,921 F1: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

CISCO SYSTEMS, INC.

Report date December 08, 2022 · Filed December 12, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,143	Reported balance After 2022-12-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-12-08 · Grant · Acquired 5,001 · Balance 24,143 F1: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code. F2: Includes 1,751 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock. F3: Since the reporting person's last Form 4 filing, the reporting person transferred 12,768 shares relating to vested deferred restricted stock units and 1,264 dividend equivalents accrued on vested deferred restricted stock units previously reported as held directly by the reporting person in a transaction exempt from reporting under Section 16(a) of the Exchange Act, and such shares are no longer beneficially owned by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code.

F2: Includes 1,751 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock.

F3: Since the reporting person's last Form 4 filing, the reporting person transferred 12,768 shares relating to vested deferred restricted stock units and 1,264 dividend equivalents accrued on vested deferred restricted stock units previously reported as held directly by the reporting person in a transaction exempt from reporting under Section 16(a) of the Exchange Act, and such shares are no longer beneficially owned by the reporting person.

SkinHealth Systems Inc.

Report date June 16, 2025 · Filed June 18, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	5,994,820	Reported balance After 2025-06-16 transaction · row 1 1 source row Row 1 · 2025-06-16 · Grant · Acquired 73,051 · Balance 5,994,820 F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time.
Class A Common StockSEC Table I · non-derivative	IndirectBy Triplet	1,681,771	Reported balance Holding disclosure · report date 2025-06-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,681,771 F2: Represents securities held by Triplet Enterprises III, LLC ("Triplet"). The reporting person is the managing member of Triplet and may be deemed to beneficially own the securities held by Triplet, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy Trust	1,121,180	Reported balance Holding disclosure · report date 2025-06-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,121,180 F3: Represents securities held by the Saunders Family Trust ("Trust"). The reporting person has voting and dispositive control over these securities and thus the reporting person may be deemed to beneficially own the securities held by Trust, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time.

F2: Represents securities held by Triplet Enterprises III, LLC ("Triplet"). The reporting person is the managing member of Triplet and may be deemed to beneficially own the securities held by Triplet, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.

F3: Represents securities held by the Saunders Family Trust ("Trust"). The reporting person has voting and dispositive control over these securities and thus the reporting person may be deemed to beneficially own the securities held by Trust, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Allergan plc

Report date May 08, 2020 · Filed May 12, 2020

Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-08 · Disposition to issuer · Disposed 149,384.28 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-05-08 · Disposition to issuer · Disposed 79,805 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $224.00 · Expires 2023-05-08	Direct	Reported balance After 2020-05-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-05-08 · Disposition to issuer · Disposed 104,651 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $91.13 · Expires 2023-09-30	Direct	Reported balance After 2020-05-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-05-08 · Disposition to issuer · Disposed 3,291 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12	Direct	Reported balance After 2020-05-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-05-08 · Disposition to issuer · Disposed 1,018 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2021-08-22	Direct	Reported balance After 2020-05-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-05-08 · Disposition to issuer · Disposed 9,446 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $73.14 · Expires 2022-08-22	Direct	Reported balance After 2020-05-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-05-08 · Disposition to issuer · Disposed 3,691 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $90.22 · Expires 2023-08-14	Direct	Reported balance After 2020-05-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-05-08 · Disposition to issuer · Disposed 2,790 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $91.13 · Expires 2023-09-30	Direct	Reported balance After 2020-05-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-05-08 · Disposition to issuer · Disposed 219,667 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12	Direct	Reported balance After 2020-05-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-05-08 · Disposition to issuer · Disposed 62,547 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12	Direct	Reported balance After 2020-05-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-05-08 · Disposition to issuer · Disposed 1 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-05-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-05-08 · Disposition to issuer · Disposed 83,936 · Balance 0 F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.

F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Merck & Co., Inc.

Report date November 03, 2009 · Filed November 04, 2009

Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Not disclosed	Reported balance After 2009-11-03 transaction · row 1 1 source row Row 1 · 2009-11-03 · Disposition to issuer · Disposed 50,783 · Balance Not disclosed F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18	Direct	0	Reported balance After 2009-11-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2009-11-03 · Disposition to issuer · Disposed 120,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.27 · Expires 2013-10-31	Direct	0	Reported balance After 2009-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-11-03 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30	Direct	0	Reported balance After 2009-11-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2009-11-03 · Disposition to issuer · Disposed 140,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24	Direct	0	Reported balance After 2009-11-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2009-11-03 · Disposition to issuer · Disposed 130,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30	Direct	0	Reported balance After 2009-11-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2009-11-03 · Disposition to issuer · Disposed 130,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30	Direct	0	Reported balance After 2009-11-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2009-11-03 · Disposition to issuer · Disposed 130,100 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2014-02-22	Direct	0	Reported balance After 2009-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2009-11-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Phantom Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2009-11-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2009-11-03 · Disposition to issuer · Disposed 65,587.15 · Balance 0 F4: Each unit of phantom stock is the economic equivalent of one share of common stock. F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.

F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.

F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F4: Each unit of phantom stock is the economic equivalent of one share of common stock.

F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 03, 2009 Filed Nov 4, 2009 23:01 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	45,000	Not disclosed Strike: $15.27	Not disclosed	Disclosure SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,000 shares Expires 2013-10-31 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 23:01 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	120,000	Not disclosed Strike: $19.23	Not disclosed	Disclosure SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 120,000 shares Expires 2013-05-18 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 23:01 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerCommon Shares	50,783	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-09-051079 · c91857_4x1.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document
May 01, 2009 Filed May 5, 2009 18:13 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	130,100	Not disclosed Strike: $22.91	Not disclosed	Disclosure SEC source: 0000310158-09-000055 · sau733.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,100 Underlying: Common Shares · 130,100 shares Expires 2016-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2010, 2011 and 2012. The vesting of 26,020 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2009 year. Read SEC document
April 01, 2009 Filed Apr 3, 2009 18:47 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionDeferred Stock Unit Award · Derivative	25,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-09-000024 · sau723.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document
April 01, 2009 Filed Apr 3, 2009 18:47 UTC	Merck & Co., Inc. SGP · Entity 2807	Tax withholdingCommon Shares	11,588	$23.70	$274,635.60	Disclosure SEC source: 0000310158-09-000024 · sau723.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,783 Read SEC document
April 01, 2009 Filed Apr 3, 2009 18:47 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionCommon Shares	25,000	$0.00	$0.00	Disclosure SEC source: 0000310158-09-000024 · sau723.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document
February 27, 2009 Filed Mar 3, 2009 22:14 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantPhantom Stock Unit · Derivative	65,203	$17.39	$1,133,880.17	Disclosure SEC source: 0000310158-09-000012 · sau704.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,203 Underlying: Common Shares · 65,203 shares Expires not disclosed F1 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. F1 · derivative.exercise_date: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. F1 · derivative.expiration_date: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. Read SEC document
May 01, 2008 Filed May 5, 2008 21:08 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	130,000	Not disclosed Strike: $18.85	Not disclosed	Disclosure SEC source: 0000310158-08-000044 · sau668.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Shares · 130,000 shares Expires 2015-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2009, 2010 and 2011. The vesting of 26,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2008 year. Read SEC document
April 25, 2008 Filed Apr 29, 2008 20:10 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionDeferred Stock Unit Award · Derivative	25,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-08-000024 · sau656.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document
April 25, 2008 Filed Apr 29, 2008 20:10 UTC	Merck & Co., Inc. SGP · Entity 2807	Tax withholdingCommon Shares	9,088	$18.64	$169,400.32	Disclosure SEC source: 0000310158-08-000024 · sau656.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,371 Read SEC document
April 25, 2008 Filed Apr 29, 2008 20:10 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionCommon Shares	25,000	$0.00	$0.00	Disclosure SEC source: 0000310158-08-000024 · sau656.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document
May 01, 2007 Filed May 3, 2007 14:18 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	140,000	Not disclosed Strike: $31.57	Not disclosed	Disclosure SEC source: 0000310158-07-000030 · sau613.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Shares · 140,000 shares Expires 2014-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2008, 2009 and 2010. The vesting of 28,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2007 year. Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionOption (right to buy) · Derivative	45,000	Not disclosed Strike: $15.27	Not disclosed	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · derivative · entry 9 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2013-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on November 2 of each of 2004, 2005 and 2006. Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	Tax withholdingCommon Shares	9,471	$31.85	$301,651.35	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 8 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,459 Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	SaleCommon Shares	1,729	$31.67	$54,757.43	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 7 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,930 Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	SaleCommon Shares	1,200	$31.66	$37,992.00	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 6 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,659 Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	SaleCommon Shares	2,500	$31.65	$79,125.00	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 5 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,859 Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	SaleCommon Shares	20,700	$31.64	$654,948.00	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 4 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,359 Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	SaleCommon Shares	6,400	$31.63	$202,432.00	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,059 Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	SaleCommon Shares	3,000	$31.62	$94,860.00	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,459 Read SEC document
April 27, 2007 Filed May 1, 2007 17:19 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionCommon Shares	45,000	$15.27	$687,150.00	Disclosure SEC source: 0000310158-07-000016 · sau604.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 01, 2006 Filed Dec 5, 2006 14:00 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionDeferred Stock Unit Award · Derivative	15,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-06-000148 · sau581.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document
December 01, 2006 Filed Dec 5, 2006 14:00 UTC	Merck & Co., Inc. SGP · Entity 2807	Tax withholdingCommon Shares	6,953	$21.93	$152,479.29	Disclosure SEC source: 0000310158-06-000148 · sau581.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,459 Read SEC document
December 01, 2006 Filed Dec 5, 2006 14:00 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionCommon Shares	15,000	$0.00	$0.00	Disclosure SEC source: 0000310158-06-000148 · sau581.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document
November 01, 2006 Filed Nov 3, 2006 19:21 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionDeferred Stock Unit Award · Derivative	25,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-06-000109 · sau568.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document
November 01, 2006 Filed Nov 3, 2006 19:21 UTC	Merck & Co., Inc. SGP · Entity 2807	Tax withholdingCommon Shares	11,588	$21.97	$254,588.36	Disclosure SEC source: 0000310158-06-000109 · sau568.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,412 Read SEC document
November 01, 2006 Filed Nov 3, 2006 19:21 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionCommon Shares	25,000	$0.00	$0.00	Disclosure SEC source: 0000310158-06-000109 · sau568.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document
May 19, 2006 Filed May 23, 2006 20:35 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	120,000	Not disclosed Strike: $19.23	Not disclosed	Disclosure SEC source: 0000310158-06-000070 · sau539.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Shares · 120,000 shares Expires 2013-05-18 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under Schering-Plough Corporation 2006 Stock Incentive Plan and exerciseable in one-third increments on April 1 of 2007, 2008 and 2009. The vesting of 24,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the year 2006. Read SEC document
May 19, 2006 Filed May 23, 2006 20:35 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantDeferred Stock Unit Award · Derivative	25,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-06-000070 · sau539.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under Schering-Plough Corporation 2006 Stock Incentive Plan. All of the shares become deliverable on April 1, 2009 subject to Schering-Plough's satisfaction of certain performance criteria for the year 2006. F3 · derivative.expiration_date: Not Applicable. Read SEC document
April 25, 2005 Filed Apr 27, 2005 20:06 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	130,000	Not disclosed Strike: $20.70	Not disclosed	Disclosure SEC source: 0000310158-05-000028 · sau481.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Shares · 130,000 shares Expires 2015-04-24 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on April 26 of each 2006, 2007 and 2008, subject to Schering-Plough's satisfaction of certain performance criteria for the year 2005 with respect to 26,000 option shares. Read SEC document
April 25, 2005 Filed Apr 27, 2005 20:06 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantDeferred Stock Unit Award · Derivative	25,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-05-000028 · sau481.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan. All of the shares become deliverable on April 25, 2008, subject to Schering-Plough's satisfaction of certain performance criteria for the year 2005. F3 · derivative.expiration_date: Not Applicable. Read SEC document
February 23, 2004 Filed Feb 25, 2004 19:39 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantPhantom Stock Units · Derivative	291,949	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-04-000039 · sau364.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,949 Underlying: Common Shares · 291,949 shares Expires not disclosed F7 · derivative.exercise_price: 1 for 1 F9 · price: Not Applicable. F8 · derivative.exercise_date: Includes grants under the Long-Term Performance Share Unit Incentive Plan and the Transformational Performance Contingent Shares Program. The shares of phantom stock become payable in cash upon the reporting person's termination of service as an employee of the Issuer. F8 · derivative.expiration_date: Includes grants under the Long-Term Performance Share Unit Incentive Plan and the Transformational Performance Contingent Shares Program. The shares of phantom stock become payable in cash upon the reporting person's termination of service as an employee of the Issuer. Read SEC document
February 23, 2004 Filed Feb 25, 2004 19:39 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (Right to Buy) · Derivative	100,000	Not disclosed Strike: $18.20	Not disclosed	Disclosure SEC source: 0000310158-04-000039 · sau364.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2014-02-22 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on February 24 of each 2005, 2006 and 2007. Read SEC document
February 23, 2004 Filed Feb 25, 2004 19:39 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantDeferred Stock Unit Award · Derivative	15,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-04-000039 · sau364.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan. All of the shares become deliverable on February 23, 2007. F3 · derivative.expiration_date: Not Applicable. Read SEC document
November 01, 2003 Filed Nov 4, 2003 20:24 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantDeferred Stock Unit Award · Derivative	25,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-03-000106 · sau258.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan. All of the shares become deliverable on November 1, 2006. F3 · derivative.expiration_date: Not Applicable. Read SEC document
November 01, 2003 Filed Nov 4, 2003 20:24 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	90,000	Not disclosed Strike: $15.27	Not disclosed	Disclosure SEC source: 0000310158-03-000106 · sau258.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2013-10-31 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on November 2 of each 2004, 2005 and 2006. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.